


Novamind and Wholeness Center partner on a psychedelic therapy protocol for frontline healthcare workers
Group ketamine therapy for healthcare workers with Covid-based stress & trauma led by Dr. Scott Shannon and Dr. Reid Robison
Learn moreGroup ketamine therapy for healthcare workers with Covid-based stress & trauma led by Dr. Scott Shannon and Dr. Reid Robison
Learn moreNovamind’s Cedar Clinical Research (CCR) is a contract research organization leading clinical research in emerging therapies and psychedelic medicine for major pharmaceutical companies and world-renowned academic institutions. Research sites are co-located with Novamind’s psychiatry clinics, forming a collaborative relationship and allowing for patient recruitment from a large population with diverse needs.
Novamind’s Cedar Clinical Research (CCR) is a contract research organization leading clinical research in emerging therapies and psychedelic medicine for major pharmaceutical companies and world-renowned academic institutions. Research sites are co-located with Novamind’s psychiatry clinics, forming a collaborative relationship and allowing for patient recruitment from a large population with diverse needs.
Phase I-IV clinical trials focused on psychedelics and mental health
Our team is led by Dr. Paul Thielking, a board-certified psychiatrist in psychiatry, hospice and palliative medicine, and integrative medicine. Dr. Thielking has extensive experience creating innovative group therapy interventions for patients with serious illness and is currently the principal investigator for a psilocybin enhanced group psychotherapy intervention for cancer patients with depression.
From a pivotal ketamine clinical trial for Treatment-Resistant Major Depressive Disorder in 2012 to completing their first study of Emotion-Focused Ketamine-Assisted Psychotherapy (EF-KAP) in 2020, Cedar Clinical Research (CCR) has developed a deep foundation of expertise across a broad spectrum of research. CCR is currently contracted for eight clinical trials for companies including Merck & Co., Bionomics and Karuna Therapeutics.